<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>1688-0390</journal-id>
<journal-title><![CDATA[Revista Médica del Uruguay]]></journal-title>
<abbrev-journal-title><![CDATA[Rev. Méd. Urug.]]></abbrev-journal-title>
<issn>1688-0390</issn>
<publisher>
<publisher-name><![CDATA[Sindicato Médico del Uruguay]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S1688-03902024000301702</article-id>
<article-id pub-id-type="doi">10.29193/rmu.40.3.8</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Bomba de infusión intratecal programable de morfina en paciente con dolor oncológico refractario]]></article-title>
<article-title xml:lang="en"><![CDATA[Programmable intrathecal morphine infusion pump in a patient with refractory oncological pain]]></article-title>
<article-title xml:lang="pt"><![CDATA[Bomba de infusão intratecal programável de morfina em paciente com dor oncológica refratária]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Papa]]></surname>
<given-names><![CDATA[Patricia]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Buela]]></surname>
<given-names><![CDATA[Leticia]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Prinzo]]></surname>
<given-names><![CDATA[Humberto]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Unidad de Cuidados Paliativos de Médica Uruguaya  ]]></institution>
<addr-line><![CDATA[Montevideo ]]></addr-line>
<country>Uruguay</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Universidad de la República Uruguay Unidad Académica de Neurocirugía ]]></institution>
<addr-line><![CDATA[Montevideo ]]></addr-line>
<country>Uruguay</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>00</month>
<year>2024</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>00</month>
<year>2024</year>
</pub-date>
<volume>40</volume>
<numero>3</numero>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.edu.uy/scielo.php?script=sci_arttext&amp;pid=S1688-03902024000301702&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.edu.uy/scielo.php?script=sci_abstract&amp;pid=S1688-03902024000301702&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.edu.uy/scielo.php?script=sci_pdf&amp;pid=S1688-03902024000301702&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen El control del dolor es uno de los desafíos más importantes en el ámbito de cuidados paliativos y tiene un profundo impacto en la calidad de vida de los pacientes. En la mayoría de los casos, el dolor crónico oncológico severo puede ser controlado con opioides; sin embargo, hay una población de pacientes, estimada entre 10 a 20%, que experimenta dolor refractario que requiere abordajes más complejos. En pacientes con dolor intratable o efectos adversos intolerables, la terapia basada en la infusión intratecal de opioides debe ser considerada como parte de la estrategia terapéutica. Presentamos el caso de una paciente con un tumor maligno de mediastino anterior con dolor refractario a pesar de altas dosis de opioides y coadyuvantes. Dada la refractariedad del síntoma, se decide colocar bomba intratecal de morfina para disminuir dosis de opioides y optimizar analgesia. La dosis inicial se titula progresivamente en respuesta al reporte de la paciente y la evaluación clínica. La paciente falleció tranquila y sin dolor, con una dosis de morfina intratecal de 4500 &#956;g/día. Se concluye que la administración intratecal de analgésicos opioides mediante el implante de dispositivos programables de infusión continua para pacientes con dolor oncológico refractario es una estrategia efectiva y segura, basada en la evidencia, que permite optimizar la analgesia cuando otras técnicas han fallado.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract Pain control is one of the most important challenges in the field of palliative care and has a profound impact on patients&#8217; quality of life. In most cases, severe oncological chronic pain can be managed with opioids; however, there is a population of patients, estimated to be between 10% and 20%, who experience refractory pain that requires more complex approaches. In patients with intractable pain or intolerable adverse effects, therapy based on intrathecal opioid infusion should be considered as part of the therapeutic strategy. We present the case of a patient with a malignant tumor in the anterior mediastinum who had refractory pain despite high doses of opioids and adjuvants. Given the refractory nature of the symptom, it was decided to place an intrathecal morphine pump to reduce opioid doses and optimize analgesia. The initial dose is titrated progressively in response to the patient&#8217;s reports and clinical evaluation. The patient passed away peacefully and painlessly, with an intrathecal morphine dose of 4500 &#956;g/day. It is concluded that the intrathecal administration of opioid analgesics through the implantation of programmable continuous infusion devices for patients with refractory oncological pain is an effective and safe strategy, based on evidence, that allows for the optimization of analgesia when other techniques have failed.]]></p></abstract>
<abstract abstract-type="short" xml:lang="pt"><p><![CDATA[Resumo O controle da dor é um dos desafios mais importantes no campo dos cuidados paliativos e tem um profundo impacto na qualidade de vida dos pacientes. Na maioria dos casos, a dor crônica oncológica severa pode ser controlada com opioides; no entanto, há uma população de pacientes, estimada entre 10% e 20%, que experimenta dor refratária e requer abordagens mais complexas. Em pacientes com dor intratável ou efeitos adversos intoleráveis, a terapia baseada na infusão intratecal de opioides deve ser considerada como parte da estratégia terapêutica. Apresentamos o caso de uma paciente com um tumor maligno no mediastino anterior que apresentava dor refratária, apesar de altas doses de opioides e coadjuvantes. Dada a refratariedade do sintoma, decidiu-se implantar uma bomba intratecal de morfina para reduzir as doses de opioides e otimizar a analgesia. A dose inicial é titulada progressivamente em resposta aos relatos da paciente e à avaliação clínica. A paciente faleceu tranquila e sem dor, com uma dose de morfina intratecal de 4500 &#956;g/dia. Conclui-se que a administração intratecal de analgésicos opioides por meio do implante de dispositivos programáveis de infusão contínua para pacientes com dor oncológica refratária é uma estratégia eficaz e segura, baseada em evidências, que permite otimizar a analgesia quando outras técnicas falharam.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Dolor oncológico]]></kwd>
<kwd lng="es"><![CDATA[Morfina intratecal]]></kwd>
<kwd lng="es"><![CDATA[Bomba programable]]></kwd>
<kwd lng="en"><![CDATA[Oncological pain]]></kwd>
<kwd lng="en"><![CDATA[Intrathecal morphine]]></kwd>
<kwd lng="en"><![CDATA[Programmable pump]]></kwd>
<kwd lng="pt"><![CDATA[Dor oncológica]]></kwd>
<kwd lng="pt"><![CDATA[Morfina intratecal]]></kwd>
<kwd lng="pt"><![CDATA[Bomba programável]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[van den Beuken-van Everdingen]]></surname>
<given-names><![CDATA[MHJ]]></given-names>
</name>
<name>
<surname><![CDATA[Hochstenbach]]></surname>
<given-names><![CDATA[LMJ]]></given-names>
</name>
<name>
<surname><![CDATA[Joosten]]></surname>
<given-names><![CDATA[EAJ]]></given-names>
</name>
<name>
<surname><![CDATA[Tjan-Heijnen]]></surname>
<given-names><![CDATA[VCG]]></given-names>
</name>
<name>
<surname><![CDATA[Janssen]]></surname>
<given-names><![CDATA[DJA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Update on prevalence of pain in patients with cancer: Systematic review and meta-analysis]]></article-title>
<source><![CDATA[J Pain Symptom Manage]]></source>
<year>2016</year>
<volume>51</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>1070-90</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mercadante]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The patient with difficult cancer pain]]></article-title>
<source><![CDATA[Cancers]]></source>
<year>2019</year>
<volume>11</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>565</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gulati]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Puttanniah]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Hung]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Malhotra]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Considerations for evaluating the use of intrathecal drug delivery in the oncologic patient]]></article-title>
<source><![CDATA[Curr Pain Headache Rep]]></source>
<year>2014</year>
<volume>18</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>391</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hernández]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Martínez]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Prinzo]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Tratamiento neuroquirúrgico del dolor]]></article-title>
<source><![CDATA[Neurocirugía funcional y estereotáxica: conceptos de interés general]]></source>
<year>2015</year>
<page-range>117-52</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ayala]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Pietropinto]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Ayala]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Analgesia con morfina intratecal por bomba de infusión implantada en un caso de dolor crónico no oncológico]]></article-title>
<source><![CDATA[Anest Analg Reanim]]></source>
<year>2013</year>
<volume>26</volume>
<page-range>2</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Reddy]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Yennurajalingam]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Bruera]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Dual opioid therapy using methadone as a coanalgesic]]></article-title>
<source><![CDATA[Expert Opin Drug Saf]]></source>
<year>2015</year>
<volume>14</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>181-2</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Borja Mugabure Bujedo]]></surname>
<given-names><![CDATA[MM]]></given-names>
</name>
<name>
<surname><![CDATA[Lasuen Aguirre]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Enfoque terapéutico práctico sobre la administración de fármacos intratecales para el dolor crónico]]></article-title>
<source><![CDATA[Revisión narrativa MPJ]]></source>
<year>2021</year>
<volume>1</volume>
<page-range>21-35</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8.</label><nlm-citation citation-type="">
<collab>US Food and Drug Administration</collab>
<source><![CDATA[Use caution with implanted pumps for intrathecal administration of medicines for pain management: FDA safety communication]]></source>
<year>2018</year>
<page-range>2-5</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Prager]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Deer]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Levy]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Bruel]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Buchser]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Caraway]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Best Practices for intrathecal drug delivery for pain]]></article-title>
<source><![CDATA[Neuromodulation]]></source>
<year>2014</year>
<volume>17</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>354-72</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Deer]]></surname>
<given-names><![CDATA[TR]]></given-names>
</name>
<name>
<surname><![CDATA[Hayek]]></surname>
<given-names><![CDATA[SM]]></given-names>
</name>
<name>
<surname><![CDATA[Pope]]></surname>
<given-names><![CDATA[JE]]></given-names>
</name>
<name>
<surname><![CDATA[Lamer]]></surname>
<given-names><![CDATA[TJ]]></given-names>
</name>
<name>
<surname><![CDATA[Hamza]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Grider]]></surname>
<given-names><![CDATA[JS]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The polyanalgesic consensus conference (PACC): Recommendations for trialing of intrathecal drug delivery infusion therapy]]></article-title>
<source><![CDATA[Neuromodulation]]></source>
<year>2017</year>
<volume>20</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>133-54</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kim]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Saidov]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Mandhare]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Shuster]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Role of pretrial systemic opioid requirements, intrathecal trial dose, and non-psychological factors as predictors of outcome for intrathecal pump therapy: one clinician&#8217;s experience with lumbar postlaminectomy pain]]></article-title>
<source><![CDATA[Neuromodulation]]></source>
<year>2011</year>
<volume>14</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>165-75</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sindt]]></surname>
<given-names><![CDATA[JE]]></given-names>
</name>
<name>
<surname><![CDATA[Odell]]></surname>
<given-names><![CDATA[DW]]></given-names>
</name>
<name>
<surname><![CDATA[Tariq]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Presson]]></surname>
<given-names><![CDATA[AP]]></given-names>
</name>
<name>
<surname><![CDATA[Zhang]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Brogan]]></surname>
<given-names><![CDATA[SE]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Initial intrathecal dose titration and predictors of early dose escalation in patients with cancer using a 100: 1 oral to intrathecal morphine conversion ratio]]></article-title>
<source><![CDATA[Neuromodulation]]></source>
<year>2021</year>
<volume>24</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>1157-66</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Deer]]></surname>
<given-names><![CDATA[TR]]></given-names>
</name>
<name>
<surname><![CDATA[Pope]]></surname>
<given-names><![CDATA[JE]]></given-names>
</name>
<name>
<surname><![CDATA[Hayek]]></surname>
<given-names><![CDATA[SM]]></given-names>
</name>
<name>
<surname><![CDATA[Bux]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Buchser]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Eldabe]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[De Andrés]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The Polyanalgesic Consensus Conference (PACC): Recommendations on Intrathecal Drug Infusion Systems Best Practices and Guidelines]]></article-title>
<source><![CDATA[Neuromodulation]]></source>
<year>2017</year>
<volume>20</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>405-6</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Deer]]></surname>
<given-names><![CDATA[TR]]></given-names>
</name>
<name>
<surname><![CDATA[Smith]]></surname>
<given-names><![CDATA[HS]]></given-names>
</name>
<name>
<surname><![CDATA[Burton]]></surname>
<given-names><![CDATA[AW]]></given-names>
</name>
<name>
<surname><![CDATA[Pope]]></surname>
<given-names><![CDATA[JE]]></given-names>
</name>
<name>
<surname><![CDATA[Doleys]]></surname>
<given-names><![CDATA[DM]]></given-names>
</name>
<name>
<surname><![CDATA[Levy]]></surname>
<given-names><![CDATA[RM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Comprehensive consensus based guidelines on intrathecal drug delivery systems in the treatment of pain caused by cancer pain]]></article-title>
<source><![CDATA[Pain Physician]]></source>
<year>2011</year>
<volume>14</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>E283-312</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
